|
Oncogenes and Tumor Suppressors
Citations 171-180 of 795 total displayed.
|
Past content
(since May 2000):
|
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
- Ting-Lei Gu, Valerie L. Goss, Cynthia Reeves, Lana Popova, Julie Nardone, Joan MacNeill, Denise K. Walters, Yi Wang, John Rush, Michael J. Comb, Brian J. Druker, and Roberto D. Polakiewicz
Blood 2006; 108: 4202-4204.
[Abstract]
[Full text]
[PDF]
Clinical implications of FLT3 mutations in pediatric AML
- Soheil Meshinchi, Todd A. Alonzo, Derek L. Stirewalt, Michel Zwaan, Martin Zimmerman, Dirk Reinhardt, Gertjan J. L. Kaspers, Nyla A. Heerema, Robert Gerbing, Beverly J. Lange, and Jerald P. Radich
Blood 2006; 108: 3654-3661.
[Abstract]
[Full text]
[PDF]
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
- Daniel J. DeAngelo, Richard M. Stone, Mark L. Heaney, Stephen D. Nimer, Ronald L. Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nick Holford, Peter T. Curtin, Brian J. Druker, and Michael C. Heinrich
Blood 2006; 108: 3674-3681.
[Abstract]
[Full text]
[PDF]
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
- Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J. Levis, and Donald Small
Blood 2006; 108: 3262-3270.
[Abstract]
[Full text]
[PDF]
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53
- Frank Dicker, Arnon P. Kater, Carlos E. Prada, Tetsuya Fukuda, Januario E. Castro, Guizhen Sun, Jean Y. Wang, and Thomas J. Kipps
Blood 2006; 108: 3450-3457.
[Abstract]
[Full text]
[PDF]
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
- Mark Levis, Patrick Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel DeAngelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, and Donald Small
Blood 2006; 108: 3477-3483.
[Abstract]
[Full text]
[PDF]
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17)
- Elise Chapiro, Eric Delabesse, Vahid Asnafi, Corinne Millien, Frederic Davi, Elizabeth Nugent, Kheira Beldjord, Torsten Haferlach, David Grimwade, and Elizabeth A. Macintyre
Blood 2006; 108: 3484-3493.
[Abstract]
[Full text]
[PDF]
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
- Steven Knapper, Kenneth I. Mills, Amanda F. Gilkes, Steve J. Austin, Val Walsh, and Alan K. Burnett
Blood 2006; 108: 3494-3503.
[Abstract]
[Full text]
[PDF]
Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin
- Selim Corbacioglu, Mehtap Kilic, Mike-Andrew Westhoff, Dirk Reinhardt, Simone Fulda, and Klaus-Michael Debatin
Blood 2006; 108: 3504-3513.
[Abstract]
[Full text]
[PDF]
The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia
- Pieter Van Vlierberghe, Martine van Grotel, H. Berna Beverloo, Charles Lee, Tryggvi Helgason, Jessica Buijs-Gladdines, Monique Passier, Elisabeth R. van Wering, Anjo J. P. Veerman, Willem A. Kamps, Jules P. P. Meijerink, and Rob Pieters
Blood 2006; 108: 3520-3529.
[Abstract]
[Full text]
[PDF]
|
|
